Related Experiment Video
Updated: May 1, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
19.4K
[Prognostic and predictive molecular markers for urologic cancers].
A Hartmann1, T Schlomm, S Bertz
1Institut für Pathologie, Universität Erlangen, Erlangen, Deutschland.
Der Urologe. Ausg. A
|April 5, 2014
Summary
Molecular markers are emerging for urogenital cancers, offering potential for targeted therapies and improved prognostics. Integrating these with traditional methods may enhance cancer patient management and treatment selection.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Context:
- Molecular prognostic factors and genetic alterations are increasingly utilized for targeted cancer therapies.
- Numerous molecular markers for urogenital cancers have been identified but are not yet in clinical use.
- Advancements in next-generation sequencing have detailed molecular changes in prostate cancer.
Purpose:
- To review the current state and future potential of molecular markers in urogenital cancers.
- To highlight the role of molecular markers in refining prognosis and guiding treatment decisions.
- To explore the clinical relevance of molecular markers for prostate, urothelial, and renal cell carcinomas.
Summary:
- Prostate cancer research shows that combining histopathology with molecular markers can improve prognostic accuracy, supporting active surveillance.
- Urothelial carcinoma involves histopathological factors, tumor proliferation, oncogene mutations, and invasion/metastasis genes, with gene expression profiles distinguishing aggressive tumors.
- Renal cell carcinoma has identified molecular markers associated with metastasis and survival, some validated as independent prognostic markers.
Impact:
- Improved prognostic accuracy for urogenital cancers through integrated molecular and histopathological assessments.
- Potential for more precise patient stratification, enabling active surveillance and personalized perioperative or adjuvant systemic therapies.
- Future clinical application of molecular markers could optimize treatment selection, particularly for patients with organ-confined tumors at high risk of metastasis.
